Indolent T-Cell Non-Hodgkin Lymphoma — Trials

Indolent T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

134 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 33
Recruiting: 16
Ph III recruiting: 0
Growth YoY: —
Industry share: 15%
Top sponsor: City of Hope Medical Center
Termination share: 46.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (31)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07714187	A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides	not yet recruiting	Phase 1	30	SecuraBioINDUSTRY	1	Jul 20, 2026	clinicaltrials
NCT07691450	Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma	not yet recruiting	Phase 1	40	City of Hope Medical CenterOTHER	1	Jul 9, 2026	clinicaltrials